Search
Adagrasib
go.drugbank.com/drugs/DB15568ApprovedInvestigational[A254052,A254057,A254946] In February 2022, the FDA accepted a new drug application (NDA) for adagrasib for the treatment of patients with previously treated KRAS<sup>G12C</sup>–positive NSCLC. … [L44361,L44366] Adagrasib joins [sotorasib] as another KRAS<sup>G12C</sup> inhibitor approved by the FDA.[A254062]
Synonyms: ((2s)-4-(7-(8-chloronaphthalen-1-yl)-2-(((2s)-1- methylpyrrolidin-2-yl)methoxy)-5,6,7,8- tetrahydropyrido(3,4-d)pyrimidin-4-yl)-1-(2-fluoroprop2-enoyl)piperazin-2-yl)acetonitrile, 2-piperazineacetonitrile, 4-(7-(8-chloro-1-naphthalenyl)-5,6,7,8-tetrahydro-2-(((2s)-1-methyl-2-pyrrolidinyl)methoxy)pyrido(3,4-d)pyrimidin-4-yl)-1-(2-fluoro-1-oxo-2-propen-1-yl)-, (2s)-Vestronidase alfa
go.drugbank.com/drugs/DB12366ApprovedInvestigationalVestronidase alfa, or vestronidase alfa-vjbk, is a recombinant human lysosomal beta glucuronidase that is a purified enzyme produced by recombinant DNA technology in a Chinese hamster ovary cell line. … Some affected individuals do not survive infancy, while others may live into adolescence or adulthood and patients may experience developmental delay and progressive intellectual disability [FDA Label]
Potassium perchlorate
go.drugbank.com/drugs/DB09418ApprovedWithdrawnThe use of potassium perchlorate as a component in sealing gaskets for food containers has been revoked by the FDA following the use being abandoned by the industry [L2365]. … Potassium perchlorate acts as a competitive inhibitor of iodine uptake by the thyroid gland and attenuates the production of the thyroid hormone.
Crotalus scutulatus antivenin
go.drugbank.com/drugs/DB13891ApprovedSpecimens with type A venom, which cause a different pattern of injury than other rattlesnakes, have been reported in southern California, Nevada, Utah, Arizona, Texas, and New Mexico [L2856]. … CROFAB (crotalidae polyvalent immune fab (ovine))is a sheep-derived antivenin used for the management of adult and pediatric patients with North American crotalid envenomation [FDA label], which includes
Briakinumab
go.drugbank.com/drugs/DB05459InvestigationalAs of 2011 drug development for psoriasis has been discontinued in the U.S. and Europe. … Briakinumab is a human anti-IL-12 monoclonal antibody being developed for the treatment of a number of T-cell driven autoimmune diseases.
Narsoplimab
go.drugbank.com/drugs/DB16418ApprovedInvestigational[A241030, A241040] Narsoplimab (OMS721), a human IgG4λ anti-MASP-2 antibody, is under consideration as a treatment for hematopoietic stem cell transplant-associated TMA (HSCT-TMA/TA-TMA) and IgA nephropathy … [A241030] Evidence increasingly points to a role for the complement system in TMA.
L-Acetylleucine
go.drugbank.com/drugs/DB16956ApprovedInvestigationalLevacetylleucine (L-acetylleucine) is a modified acetylated derivative of the amino acid [leucine]. The racemic (i.e. DL-) form has been available in France since 1957 for the treatment of vertigo. … [A264439] Observational studies in patients with Niemann-Pick disease type C (NPC) suggested a beneficial symptomatic as well as neuroprotective disease-modifying effect of the DL-form of N-acetylleucine
Piperaquine
go.drugbank.com/drugs/DB13941ApprovedInvestigationalIt has come back into use in combination with the artemisinin derivative [DB11638] as part of the combination product Eurartesim [FDA Label]. … Eurartesim was first authorized for market by the European Medicines Agency in October 2011.
Mixtures: D-ARTEPP, D-ARTEPP DISPERSIBLESucralfate
go.drugbank.com/drugs/DB00364ApprovedInvestigationalSucralfate is a medication that is widely used to prevent and treat a number of diseases in the gastrointestinal tract such as duodenal ulcers [FDA label], gastro-esophageal reflux disease (GERD), gastritis … It was approved by the FDA 1982 in tablet form, and in 1994 for the suspension form [L6073, L6076].
Synonyms: Hexadeca-μ-hydroxytetracosahydroxy[μ8-[1,3,4,6-tetra-O-sulfo-β-Dfructofuranosyl-α-D-glucopyranoside tetrakis(hydrogen sulfato)8-)]]hexadecaaluminumProducts: SUCRALFATO MYLAN GENERICS, SUCRALFATO DOC GENERICIRevumenib
go.drugbank.com/drugs/DB18515ApprovedInvestigationalIt was approved by the FDA in November 2024 for the treatment of leukemia with KMT2A aberrations,[L51868,L51863] becoming the first menin inhibitor to receive FDA approval. … Menin is a scaffold protein that interacts with both the wild-type and rearranged KMT2A, which is crucial for KMT2A activity and the maintenance of _HOXA_ expression and leukemogenesis.